Pulser Inc.
Apple-Simple, Google-Smart.
Precision AI for Self-Driving Clinical Trials Investor Presentation • Seed & Series A
Mission
Revolutionize Clinical Trials with AI
The Scale of the Pain
$70B Annual Waste
The Pulser Solution
Dynamic, Adaptive Trials
How the Self-Driving Trial™ Works
AI-powered adaptive trials with synthetic data
Digitized Human Intelligence Stack
Self-learning technology platform
The Pulser Flywheel
Virtuous cycle accelerating medical innovation
invest@pulsernetwork.com | www.PulserNetwork.com | (877) 4-PULSE-AI
Mission
Pulser fuses frontline medicine with advanced mathematics to predict, prevent, and out-maneuver disease. Our patented Digitized Human Intelligence (DHI) platform turns static clinical snapshots into live, decision-ready "movies," compressing timelines and budgets for every new therapy.
Accelerate Development
Cut trial timelines by 40% while maintaining statistical power
Reduce Costs
Eliminate up to 70% of wasteful placebo groups and manual processes
De-Risk Investments
Proprietary AI provides early signals for success/failure decisions
Pulser has secured leading biopharma partnerships and is positioned to capture a $40B+ addressable market opportunity.
2
The Scale of the Pain
Clinical trials are the critical bottleneck in therapeutic development, triggering massive financial and opportunity costs:
Annual Waste
Lost every year on slow human trials
$40-70B
Per Patient Cost
Median Phase III oncology (J.P. Morgan 2024)
$41K
Avoidable Waste
Spent on fixed arms, manual exports, placebo groups
30-70%
"Investors have the same reaction every time: 'Why hasn't anyone solved this already?'" — Jeffrey Galpin MD, CEO
Source: JP Morgan 2024 cost study; Tufts CSDD 2023.
Lost time and capital delay therapies and stifle innovation.
Source: Tufts CSDD, independent analysis
3
The Pulser Solution
We've engineered a revolutionary clinical trial platform that transforms static protocols into dynamic, efficient systems:
Self-Driving Trial™
Autonomous protocol that adapts arms and sample sizes in real-time, reducing timelines by 50%
Synthetic Placebo™
AI-generated control groups from historical data, enabling 100% of volunteers to receive active therapy
Live Analytics Engine
Continuous EHR data streaming with in-place processing, eliminating manual exports and data brokering
Our proprietary technology delivers measurable competitive advantages over conventional methods:
1
Timeline Reduction
-50% through parallel processing and continuous adaptation, accelerating time-to-market
2
Cost Efficiency
30-70% reduction by eliminating redundant processes and manual intervention, maximizing ROI (see page 3)
3
Patient Engagement
+100% enrollment appeal with guaranteed active treatment arms, driving rapid recruitment
Our robust intellectual property portfolio includes eight provisional patents protecting our core technologies (US 63/943 922 – 63/944 119), creating significant barriers to entry.
invest@pulsernetwork.com | www.PulserNetwork.com | (877) 4-PULSE-AI
4
How the Self-Driving Trial™ Works
Our autonomous platform transforms clinical trials with intelligent, fully automated workflows:
1
Secure Enterprise Connectors
Seamlessly integrates with EMR systems via HIPAA-compliant, certified data pipelines.
Requires zero implementation effort from healthcare partners.
2
Advanced Signal Processing
Proprietary Hidden-Markov algorithms extract patient-state vectors from clinical data rapidly.
Enables millisecond-latency insights from vitals, labs, and notes.
3
Intelligent Allocation Engine
Adaptive-design kernel optimizes sample sizes nightly to minimize waste.
Accelerates time-to-insight by up to 40% faster over traditional clinical trials.
4
Revolutionary Synthetic Controls
Synthetic Placebo™ creates digital twins for every participant.
Ensures all patients receive active treatment with personalized matching.
5
Executive Decision Intelligence
Real-time dashboard surfaces futility, superiority, and protocol adjustments instantly.
Enables decisive action—no more months-long delays.
Eight provisional patents (US 63/943 922 – 63/944 119) secure our core technology, creating robust barriers to entry.
Faster time-to-insight claims align with current FDA guidance for adaptive clinical trial approaches. See FDA Guidance for Industry: Adaptive Designs for Clinical Trials of Drugs and Biologics (2019).
invest@pulsernetwork.com | www.PulserNetwork.com | (877) 4-PULSE-AI
5
Digitized Human Intelligence Stack
UX
Robust enterprise web portal and API suite featuring an immutable audit-trail ledger (MVP v1.2).
Orchestrator
Proprietary, GPU-powered adaptive design kernel for dynamic, real-time trial optimization (Pilot).
Core AI
Advanced Hidden-Markov models and sophisticated topology analytics (Bellman–Landauer IP) (Patented).
Feature Factory
Clinical NLP with custom transformer fine-tuning and manifold learning to identify latent patient states (Deployed).
Data Ingestion
HIPAA-compliant FHIR/HL7 streaming adapters enabling seamless enterprise integration and secure real-time data flow (Deployed).
All computation remains protected behind HIPAA-compliant firewalls; no patient data ever leaves the healthcare provider domain, guaranteeing the highest standards of security and regulatory compliance.
6
The Pulser Flywheel
This self-reinforcing business mechanism drives exponential growth for Pulser. Each new clinical trial enlarges our federated EMR data graph, enabling constantly improving machine learning models and predictive accuracy.
Improved outcomes attract more pharmaceutical sponsors to the platform, while participating hospitals generate recurring clinical data management (CDM) fees and deliver superior patient care. This virtuous cycle steadily expands the ecosystem, creating a powerful data moat and accelerating returns for all stakeholders.
Data Moat
Expanding federated EMR graph creates proprietary clinical data ecosystem
Learning Loop
AI models continuously sharpen with each new datapoint across trials
Marketplace Network Effects
Success metrics attract more pharma sponsors to the platform
Value Compounding
Hospitals earn recurring CDM fees while improving patient outcomes
invest@pulsernetwork.com | www.PulserNetwork.com | (877) 4-PULSE-AI
7
Credibility Snapshot: Pulser by the Numbers
8 Provisional Patents
Proprietary technology with robust intellectual property protection
10× Data Depth
Enhanced clinical insights through superior data architecture
30-70% Cost Saved
Significant reduction in clinical trial expenditures
50% Timeline Reduction
Dramatically faster trial completion and results
$40M+ Signed ARR Pipeline
Strong commercial traction with committed future revenue.
8
Market Size & Growth
Pulser's total addressable market is vast and accelerating within the rapidly evolving clinical trials landscape:
2024 U.S. CDM/CRO Spend
US $60–70 billion market, with 65% directly addressable by Pulser's solutions.
2032 Market Forecast
Exceeding US $80 billion, fueled by surging gene and mRNA therapy programs (GlobalData 2024).
Pulser is projected to capture approximately 1.2–2.5% market share within five years.
CAGR ≈ 6%
Industry compound annual growth rate holds steady at 6%, yet cost-reduction platforms like Pulser can unlock 4x market expansion—enabling 18–24% annual growth potential for innovators.
This is a mature sector urgently seeking innovation—87% of biopharma executives now view trial costs as "unsustainable" (McKinsey, 2023).
9
Competitive Positioning
No rival owns the entire design-to-data loop.
AI scribes / note capture
2024-25 Winner: Abridge – US $250 M Series D
What Pulser Does Differently: Live analytics in trial engine; monetized via data, not SaaS seats.
LLM safety layers
2024-25 Winner: Hippocratic AI – US $141 M Series B
What Pulser Does Differently: Patented regulator-grade guard-rails (2023).
Real-world evidence networks
2024-25 Winner: Komodo Health – US $514 M total
What Pulser Does Differently: Operates inside hospital firewalls, not in third-party clouds.
Value-based care insurers
2024-25 Winner: Devoted Health – US $2,260 M total
What Pulser Does Differently: Devoted cuts care-delivery waste; Pulser slashes R&D latency.
invest@pulsernetwork.com | www.PulserNetwork.com | (877) 4-PULSE-AI
10
Regulatory & Macro Tailwinds
Strong market forces accelerating adoption
FDA Adaptive-Design Guidance (2019)
Regulatory framework explicitly endorses dynamic study arms, creating fertile ground for Pulser's technology adoption across clinical trial ecosystems.
US $6.7 B venture inflows (DealForma Q1-25).
Capital influx into "efficiency AI" biopharma start-ups in Q1-2025 alone (DealForma), signaling massive market validation and investor confidence in our sector.
Hospital CFOs seek CRO-style revenue
Healthcare institutions actively pursuing diversified revenue streams, with Pulser seamlessly routing trial income through their existing EHR infrastructure.
These converging forces create an unprecedented market opportunity for Pulser's technology stack and business model.
11
Traction & Near-Term Roadmap
Our validated approach is delivering measurable results with a clear path to profitability
2024 Q4
Sandbox adaptive trial completed inside 1-hospital network ✓
Validated core technology with real patient data
2025 Q3
2–4 paid adaptive trials launch (oncology & rare-disease sponsors)
Initial revenue generation with tier-1 pharmaceutical partners
2026 Q2
Synthetic Placebo™ catalogue live;
Scalable recurring revenue model with proprietary technology
2027 Q1
Cash-flow break-even; platform opens to mid-tier CRO partners
Exponential growth phase with expanded market penetration
ARR > US $40,000k
Our technology-driven approach is positioned to transform clinical trial efficiency with demonstrable ROI for all stakeholders
invest@pulsernetwork.com | www.PulserNetwork.com | (877) 4-PULSE-AI
12
Financial Snapshot (USD)
Projecting strong financial growth with positive cash flow achieved by Year 3, demonstrating the scalability of our business model and path to profitability.
Key Highlights
- 46% Gross Margin projected in Year 3
- $100M Revenue by Year 3
- Positive Cash Flow of $32M achieved by Year 3
Our financial model demonstrates rapid scaling with minimal initial investment, breaking even in Year 3 with substantial positive cash flow and attractive 46% gross margins.
46%
Gross Margin
Year 3 projection
$100M
Revenue
By Year 3
$32M
Positive Cash Flow
Achieved in Year 3
invest@pulsernetwork.com | www.PulserNetwork.com | (877) 4-PULSE-AI
13
Capital Plan
Our strategic capital allocation is designed to maximize growth and achieve key milestones on our path to market leadership.
Seed / Bridge Round
Target: US $2–4M (midpoint $3.5M)
15-month runway to achieve three paying customer trials
Series A Funding
≤ US $6.5 M
- SaaS platform go-live
- 20 concurrent trials
- Four new patents
- ARR > US $80M
Our capital structure is designed to drive exponential growth while maintaining operational efficiency. The initial funding round establishes market validation while the Series A will accelerate our scale-up phase.
invest@pulsernetwork.com | www.PulserNetwork.com | (877) 4-PULSE-AI
14
Use-of-Proceeds
Our $3.5M seed funding will be strategically allocated to maximize runway and achieve critical milestones:
R&D 47% ($1.645M)
Adaptive-core hardening, GPU nodes, additional patent filings.
Payroll 27% ($945K)
Eight net new FTEs (data science, design, BD).
G&A 20% ($700K)
Legal, IP, SOC-2 audit, general overhead.
Sales & Mktg 6% ($210K)
BD travel, KOL advisory board, launch collateral.
This allocation ensures a 15-month runway to achieve our key milestone: securing three paying trial contracts.
15
Team
Our leadership team fuses globally recognized expertise in clinical research, advanced AI, computational medicine, and pharmaceutical development—delivering unmatched scientific innovation and proven commercial execution.
Jeff Galpin MD
CEO & CMO
Pioneered the first NIH gene-therapy trial; led 300+ studies as Principal Investigator.
Kirstie Bellman PhD
Chief Analytics
Three decades at the forefront of DARPA/Aerospace AI; recipient of the Telluride Tech Prize.
Chris Landauer PhD
Adv. Math & NLP
Author of 150+ pattern-analysis papers; trusted advisor to the U.S. Department of Defense.
Ken Maranga JD
Strategy & Legal
Over 40 years leading life-science litigation for global firms.
Michael Stevens PharmD
Clinical Trials
Former VP of Virology, Bristol-Myers Squibb, with deep expertise in trial execution.
Bradley Burnam
Chief Business
CEO at Turn Therapeutics; proven record of business growth and commercialization.
Brian Athey PhD
Sr Advisor
Chair of Computational Medicine, University of Michigan; visionary in healthcare analytics.
Dipak Reddy CIS
CIO
20 years leading secure IT systems for major hospital/healthcare networks.
Together, we offer DARPA-grade mathematical rigor and BMS-level execution. Our team uniquely integrates world-class modeling with proven pharmaceutical expertise to redefine clinical trial design and delivery.
invest@pulsernetwork.com | www.PulserNetwork.com | (877) 4-PULSE-AI
16
Why Invest Now
Pulser presents a rare confluence of technological innovation, market readiness, and execution capability—creating an exceptional investment opportunity with multiple paths to outsized returns.
1
Timing window
Unique convergence of adaptive-trial regulatory acceptance, abundant AI computing resources, and accelerating genomic therapy innovations create perfect market entry conditions.
2
Unique moat
First-mover advantage with proprietary end-to-end platform providing full design-to-data control and synthetic placebo network that competitors cannot easily replicate.
3
Dual upside
Immediate revenue through recurring Clinical Decision Matrix licensing plus long-term equity/royalty participation in every successfully developed therapeutic asset.
4
Execution readiness
World-class team with DARPA-level mathematical expertise and BMS-caliber clinical implementation capabilities poised to transform drug development timelines.
5
Strategic partnerships
Established relationships with key industry stakeholders create multiple pathways to rapid market adoption and revenue acceleration.
invest@pulsernetwork.com | www.PulserNetwork.com | (877) 4-PULSE-AI
17
18